2023 - Research.com Medicine in France Leader Award
Stanislas Pol mostly deals with Internal medicine, Hepatitis C virus, Gastroenterology, Immunology and Hepatitis C. His research in Internal medicine intersects with topics in Ribavirin, Surgery and Viral load. In his study, Transplantation is strongly linked to Liver disease, which falls under the umbrella field of Hepatitis C virus.
His Gastroenterology study integrates concerns from other disciplines, such as Pibrentasvir, Glecaprevir, Fibrosis, Pathology and Telaprevir. In his research on the topic of Immunology, Immunotherapy is strongly related with Virology. As part of the same scientific family, Stanislas Pol usually focuses on Hepatitis C, concentrating on Sofosbuvir and intersecting with Ledipasvir.
His main research concerns Internal medicine, Gastroenterology, Immunology, Hepatitis C virus and Virology. His studies in Internal medicine integrate themes in fields like Chronic hepatitis, Ribavirin and Surgery. His Ribavirin research incorporates elements of Regimen and Interferon.
His research integrates issues of Fibrosis, Adverse effect, Daclatasvir and Viral load in his study of Gastroenterology. Stanislas Pol interconnects Liver biopsy and Alpha interferon in the investigation of issues within Hepatitis C virus. His work deals with themes such as Liver disease, Hepatocellular carcinoma, Transplantation and Cohort, which intersect with Cirrhosis.
His primary areas of study are Internal medicine, Gastroenterology, Cirrhosis, Hepatitis C and Hepatitis C virus. His Internal medicine study incorporates themes from Ribavirin and Sofosbuvir. His studies deal with areas such as Hepatitis B, Chronic hepatitis, Coinfection, Prospective cohort study and Hepatitis B virus as well as Gastroenterology.
His studies examine the connections between Cirrhosis and genetics, as well as such issues in Liver disease, with regards to Alcoholic liver disease and Retrospective cohort study. His Hepatitis C research is multidisciplinary, relying on both Randomized controlled trial, Surgery, Hepatology, Kidney disease and Adverse effect. Research on Virology and Immunology is a part of his Hepatitis C virus study.
Internal medicine, Gastroenterology, Cirrhosis, Hepatitis C and Hepatitis C virus are his primary areas of study. He combines topics linked to Pibrentasvir with his work on Internal medicine. His Gastroenterology research is multidisciplinary, incorporating elements of Ribavirin, Sofosbuvir, Glecaprevir, Prospective cohort study and Hepatitis B virus.
Stanislas Pol has included themes like Interferon alfa and Adverse effect in his Ribavirin study. Stanislas Pol usually deals with Hepatitis C and limits it to topics linked to Randomized controlled trial and Placebo. Within one scientific family, he focuses on topics pertaining to Diabetes mellitus under Hepatitis C virus, and may sometimes address concerns connected to Kidney transplantation, Transplantation and Clinical endpoint.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Telaprevir for retreatment of HCV infection.
Stefan Zeuzem;Pietro Andreone;Stanislas Pol;Eric Lawitz.
The New England Journal of Medicine (2011)
FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.
Anaïs Vallet-Pichard;Anaïs Vallet-Pichard;Vincent Mallet;Vincent Mallet;Bertrand Nalpas;Bertrand Nalpas;Virginie Verkarre.
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Christophe Hézode;Nicole Forestier;Geoffrey Dusheiko;Peter Ferenci.
The New England Journal of Medicine (2009)
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Fabrice Carrat;Firouzé Bani-Sadr;Stanislas Pol;Eric Rosenthal.
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
David Roth;David R. Nelson;Annette Bruchfeld;Annmarie Liapakis.
The Lancet (2015)
Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?
Christian Bréchot;Valérie Thiers;Dina Kremsdorf;Bertrand Nalpas.
Hepatitis C Virus Type 1b (II) Infection in France and Italy
Jean-Baptiste Nousbaum;Stanislas Pol;Bertrand Nalpas;Paul Landais.
Annals of Internal Medicine (1995)
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.
Markus Cornberg;Homie A. Razavi;Alfredo Alberti;Enos Bernasconi.
Liver International (2011)
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890
Christophe Hézode;Hélène Fontaine;Céline Dorival;Dominique Larrey.
Journal of Hepatology (2013)
Noninvasive In Vivo Liver Fibrosis Evaluation Using Supersonic Shear Imaging: A Clinical Study on 113 Hepatitis C Virus Patients
Éric Bavu;Éric Bavu;Jean-Luc Gennisson;Mathieu Couade;Jeremy Bercoff.
Ultrasound in Medicine and Biology (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: